



# PRESS RELEASE

Monday, 18<sup>th</sup> May 2021, Mumbai

## GlaxoSmithKline Pharmaceuticals Limited announces results for the quarter and full year ended March 31, 2021

**Q4 underlying revenue growth at 6%**

**Board of Directors of the Company recommends a Dividend of Rs. 30 per equity share for the 12 months period ended March 31, 2021**

---

**GlaxoSmithKline Pharmaceuticals Limited** today declared its financial results for the quarter ended 31<sup>st</sup> March 2021. Revenue for the quarter came in at Rs 807 crores recording an underlying growth of 6%. Total Income came in at Rs 837 crores as compared to Rs 791 crores for the quarter ended 31<sup>st</sup> March 2020. PBT (before exceptional) for the quarter at Rs 180 crores recorded a growth of 9%.

Revenue for the year ended 31<sup>st</sup> March 2021 was Rs 3194 crores, declining 1% versus previous year with Total Income at Rs 3304 at the same levels as the previous year. PBT (before exceptional) for the year at Rs 722 crores improved from Rs 647 crores in previous year. EBIDTA at Rs 695 recorded a growth of 5%.

Commenting on the results, **Sridhar Venkatesh, Managing Director, GlaxoSmithKline Pharmaceuticals Limited** said,

“Our relentless patient focus helped us revitalise growth through the year and emerge with renewed resilience in Q4 as we notched double-digit growth across some of our focus brands. Our established portfolio made gains in their market share in respective categories, particularly in the anti-infectives and pain therapeutic areas which have been crucial in the fight against COVID. We also continued to maintain our leadership in dermatology. This growth has further strengthened our resolve to ensure patients get access to our medicines and vaccines that can make that lifesaving difference.

During the year we saw vaccines gaining more significance than ever, GSK continues to be the No. 1 vaccines company in the self-pay segment, propelled by impressive growth towards the end of the year with almost 40% value market share in represented segments. In September 2020, notwithstanding the lockdown, we launched Fluarix Tetra to combat influenza and continued to build on the momentum of our recently launched brand Menveo which had demonstrated promising success, positioning us to focus on our innovation pipeline and the prospect of introducing new launches

Another priority for us remains employee safety and wellbeing which are complemented by our role as a responsible corporate citizen. We have mobilised support on the ground, by donating to our established humanitarian response partner, Direct Relief in addition to the employee payroll giving initiative. We were the first multinational pharmaceutical company to return to the field as lockdown restrictions were lifted and we continue to cater to market needs with agility by leveraging the scale afforded to us by our investments in digital tools.”



## **About GlaxoSmithKline Pharmaceuticals Limited**

GlaxoSmithKline Pharmaceuticals Limited is a subsidiary of GlaxoSmithKline plc, one of the world's leading research-based pharmaceutical and healthcare companies, committed to improving the quality of human life by enabling people to do more, feel better and live longer. For more information, visit [www.gsk-india.com](http://www.gsk-india.com)

### Media Contacts:

Ransom D'Souza

Vice President Corporate Communications and Government Affairs

Email: [ransom.a.dsouza@gsk.com](mailto:ransom.a.dsouza@gsk.com)

Tel: +91 22 24959203